Seres Therapeutics(MCRB)
Focus: Seres Therapeutics is a public biotechnology company developing microbiome-based therapeutics to treat antibiotic-associated side effects and infectious diseases. Founded in 2013 and trading on NASDAQ (MCRB), the company operates at the intersection of infectious disease and microbiome science.
Profile data last refreshed 8h ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Open Jobs
4
Should You Work at Seres Therapeutics?
AI assessmentBest suited for microbiome/infectious disease specialists willing to accept pre-revenue biotech volatility in exchange for frontier science exposure; runway and hiring constraints warrant diligence on funding outlook.
Why Work Here
- Pioneer in a validated microbiome therapeutics category with 8 active clinical trials and a Phase 3 program (SER-109 for C. difficile) advancing toward potential regulatory decision
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Mid-stage
2 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$0K
Pipeline & Clinical Trials
N/A
Clinical Trials (1)
NCT02437500Expanded Access Program of SER-109 in the Treatment of Adults With Recurrent Clostridioides Difficile Infection (RCDI)
N/AHelp build intelligence for Seres Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.